Introduction
Acute OPC poisoning is widespread in agricultural developing countries. Overall its frequency has increased over the years. The toxicity of the agent and paucity of appropriate medical services has resulted in high mortality rates. 1 Majority of death occurs following self poisoning. 2 OPC poisoning is more commonly seen in rural areas. Its incidents is 20% to 30% of total poisoning cases as reported in Japan, Taiwan and Thailand.3 OPC exerts an acute toxic effect on central and peripheral nervous system by blocking acetylcholinesterase (AchE) leading to accumulation of acetylcholine (Ach) at muscarinic and nicotinic receptors. 4 The OPCs are of two groups: Phosphates and Carbamates, which bind to the active amino acid site serine on the acety1cholinesterase enzyme and phosphorylate or carbamylate it respectively. The phosphorylated enzyme is very stable, degrades slowly after days to weeks, making acety1cholinesterase essentially inactive. Carbamylated enzyme degrades within minutes to hours so that the enzyme at the site is eventually regenerated. 5 OPC poisoning effects can be summarized as: a) Muscarinic effects-salivation, bronchorrhoea, bronchospasm, lacrimation, diarrhoea, urination, emesis, miosis, excessive sweating. b) Nicotinic effects-muscle fasciculation, cramping, weakness, diaphragmatic paralysis, respiratory failure, tachycardia, hypertension. c) CNS effectsconfusion, seizure and coma. 6 The treatment options are anticholinergic drug intravenous atropine, intravenous pralidoxime to reactivate acetylcholinesterase, supportive measures and assisted ventilation. Mortality is high in hospitals without facilities for assisted ventilation.7 Pralidoxime was discovered by Wilson and Colleagues in 1950 and successfully used for patients with parathione poisoning. Its effectiveness has been much debated with many Asian clinicians for the treatment of OPC poisoning, although WHO recommended its use. 8 The results of the earlier oxime trials did not demonstrate a favourable outcome. Recent trial suggested benefit of pralidoxime in very early presentation i.e. within six hours of intoxication of moderately severe OPC poisoning patients. Oximes can produce respiratory depression, cardiac arrhythmia and neurological weakness. 9 There has been extensive debate about the effectiveness of oximes for the treatment of organophosphorus insecticide poisoning. Asian doctors have reported no benefit from pralidoxime.10 Intravenous pralidoxime is being used along with intravenous atropine for the treatment of OPC poisoning for at least one decade in many hospitals of Bangladesh. We found no study in Bangladesh comparing the effectiveness of atropine and pralidoxime, in the management of OPC poisoning patients.
This experimental study was conducted to see the usefulness of pralidoxime in the treatment of OPC poisoning patients. This study also reveals the clinical profile of OPC poisoning patients.
Materials and methods
Selection of patients: This study was a randomised clinical trial. All patients with organophosphorus compound poisoning admitted in medicine ward of Khulna medical college hospital, Khulna, Bangladesh from 15 January 2013 to 14 January 2014, were enrolled for this study. During this one year period 109 OPC poisoning patients were admitted. Informed consent was taken from the guardian of each patient. The detail history was taken and clinical examination was performed. The medical data of each patient was recorded in writing.
Ethical approval: Ethical clearance from ethical review committee of Khulna medical college was taken for this randomised clinical trial.
Treatment plan: The total number of patients were 109 and they were divided into two groups according to the alternate day of admission. All the OPC poisoning patients of one admission day was put in group (A) and all the admitted OPC poisoning patients of next day was put in group (B). The patients of group (A) was treated with atropine only and all the patients of group (B) was treated with atropine plus pralidoxime. All patients received other supportive therapy with stomach wash, i.v. fluid, antibiotics, and O2 inhalation as required. Every patient was followed up by careful clinical examination. Patients developing respiratory failure was identified by clinical examination and by using pulse oximetry. Sa02 was <80%. in 8 patients, 4 from each group developed respiratory failure during treatment. These patients were treated in ICU of Khulna medical college hospital and assisted ventilation support was given. Both groups were further analysed from the start of poisoning to arrival at hospital and upto recovery.
Laboratory studies done were: Complete blood count, Blood sugar, serum amylase, urine analysis, serum creatinine, and ECG were done according to the need of patient.
Drug: Inj atropine and Inj pralidoxime was supplied from hospital store and purchased by the patient from market when required. Each ampoule of inj atropine contained 0.6 mg atropine sulphate and each vial of inj. pralidoxime contained pralidoxime 1gm. Both drugs were used in iv route. Inj. pralidoxime was given as intravenous infusion over 4 minutes to avoid hypotension. Both antidotes were administered as per recommended dosage schedule.
Study parameters: All data regarding particulars of patient, clinical features including serious manifestations such as fasciculation, respiratory failure, adverse effects of drugs, complications and outcome of treatment in each patient were collected in predesigned proforma.
Statistical analysis: All data collected in writing were entered, saved and analyzed in SPSS programme version 22. Frequency and percentage were calculated for age distribution, gender distribution, cause of poisoning, treatment outcome as recovery and mortality. p. value was calculated by chi square test and the p <0.05 was considered as statisticaly significant.
Result
In this experimental study a total of 109 OPC poisoning patients were included. Age of these patients was from 13 to 90 years. The age distribution of the patients are shown in table 1. The incidence of poisoning was highest 33 (30.27%) in 13-18 years age group. The causes of OPC poisoning were identified as far as possible. The highest incidence of 48 (44.03%) patients was due to various familial problems. In a significant number of cases (25-22.93%) the cause was non-specific, unknown and 16 (14.67%) were due to psychosocial problems. Baseline data of the patients was also shown in Table III This study included 109 patients of OPC poisoning. The patients were divided into two groups according to the alternate day of admission. Group A of 49 patients was treated with the antidote Inj atropine iv and another group B of 60 patients was treated with inj atropine iv plus inj pralidoxime iv. All these patients received other supportive measures as needed. 
Discussion
OPC is a pesticide and used in agricultural country like Bangladesh for saving crops from the attack of insect. So this pesticide is kept in rural and also in urban houses. Some people ingest this highly poisonous compound to do self harm, even suicide. Death occasionally occurs due to respiratory failure. Intravenous atropine and intravenous pralidoxime is used as anti dote along with gastric lavage and other supportive measures. Assisted ventilation for respiratory paralysis is given in few centers where facility is available. But there is controversy regarding the effectiveness of pralidoxime. Experimental study reveals that pralidoxime is effective only in mild cases of OPC poisoning and pralidoxime is generally less potent. 11, 12 Reactivation of acetylcholinesterase (AchE) is shown to be complete when oximes are given within one hour of poisoning. 13 One study in India described the development of myopathy after the use of pralidoxime. 14 In the Bangladeshi scenario the admission of OPC poisoning patient is late. So it is rarely possible for us to use pralidoxime within one hour of poisoning. In our study a total of 109 patient was included. Among them one group of 49 patient was treated with atropine alone. Out of these patients 42 (85.72%) recovered and 7 (14.28%) died. Another group of 60 patient was treated with atropine plus pralidoxime Out of these patients 50 (83.34%) recovered and 10 (16.66%) died. Atropine plus pralidoxime intervention group shows high mortality rate in comparison with atropine alone (16.66% Vs 14.28%) but we can not conclude clearly that combination therapy is inferior to atropine (p=0.733). However we can conclude that pralidoxime intervention gives no better outcome. Clinical trial in India with atropine alone and atropine plus pralidoxime reveals that difference in the rate of mortally is not significant (p value >0.05). So the study concluded that pralidoxime in treatment of moderate to severe OPC poisoning does not add any advantage over atropine.15 Our study also reveals similar result. During this study pralidoxime was administered in patients with mild, moderate and severe toxicity of OPC poisoning irrespective of their duration of poisoning, that means in case of early and also in late admitted patients.
In this study 4(8.16%) patients of atropine treated group and 4(6.67%) patients of pralidoxime intervention group developed respiratory failure and was treated in ICU with assisted ventilation. This study revealed that OPC poisoning is a bit higher in male 51.38% (56) than in female about 48.62% (53). Mortality rate is 15.60%. Death rate is higher among female (18.87% vs 12.50%), but it fails to attain statistical significance (p=0.360).
In this study we observed that addition of pralidoxime did not increase the survival rate in comparison to the patients group treated with atropine alone. So this experimental study suggests that this costly drug pralidoxime is not necessary in the treatment of OPC poisoning patients. Further large scale study can be done using pralidoxime in patients with mild toxicity of OPC and in patients admitted in hospital within one hour of ingestion of OPC.
There is limitation of this study as we did not observed the effectiveness of pralidoxime by administering it within few hours of ingestion of OPC.
Conclusion
The benefit of pralidoxime is insignificant in the treatment of OPC poisoning patients. This experimental study reveals that addition of pralidoxime did not decrease the death rate of OPC poisoning patient. Death rate can be markedly decreased if adequate ICU management with ventilatory support can be given in all the medical college hospitals.
